ArticleOncotarget2017
Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Polymorphisms and AR: A Systematic Review and Meta-Analyses.Frontiers in genetics · 2022Pooled it
- Sesquiterpene Lactone Derivatives ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Th17/Treg cell imbalance in allergic rhinitis: mechanisms and therapeutic implications.Genes and immunity · 2026Review
- Der p1 Dendritic Cells Promote Regulatory B Cell Induced Immunotolerance Through IL-10/STAT3 in Allergic Rhinitis.Biomedicines · 2026Article
- The Associative Impact of Recreational Cannabis Use on Sinonasal Diseases.Laryngoscope investigative otolaryngology · 2025Article
- Innate and Adaptive Immune Responses to Clinical Hyaluronic Acid Fillers.Journal of cosmetic dermatology · 2025Article
- Imbalance of T cell subsets: a core event that mediates the progression of T2DM and its complications.Frontiers in immunology · 2025Review
- Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor.Cancer immunology research · 2024Article
- Article
- Cang-ai volatile oil alleviates nasal inflammation via Th1/Th2 cell imbalance regulation in a rat model of ovalbumin-induced allergic rhinitis.Frontiers in pharmacology · 2024Article
- Sex-based differences in effector cells of the adaptive immune system during Alzheimer's disease and related dementias.Neurobiology of disease · 2023Review
- Neuroimmune communication in allergic rhinitis.Frontiers in neurology · 2023Review
- Salivary interleukin-17A and interferon-γ levels are elevated in children with food allergies in China.Frontiers in immunology · 2023Article
- [Diagnostic value of a novel test paper detection of ECP in nasal secretion for allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2022Article
- Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers.Allergy · 2022Article
- Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models.Clinical reviews in allergy & immunology · 2022Review
- Diesel exhaust particles increase nasal symptoms and IL-17A in house dust mite-induced allergic mice.Scientific reports · 2021Article
- Association of interleukin-12B rs6887695 with susceptibility to allergic rhinitis.Immunologic research · 2021Article
- Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition.Translational lung cancer research · 2021Article
- Interleukin-17A up-regulates thymic stromal lymphopoietin production by nasal fibroblasts from patients with allergic rhinitis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) has long been considered to predominantly involve the actions of Th2 cells, with relatively small contributions from Th1 cells. In recent years, the discovery of Th17 and regulatory T (Treg) cells has rendered the Th1/Th2 balance paradigm more complex and expanded our understanding of the pathogenesis of AR. IL-17, a key cytokine produced by Th17 cells, is known to induce allergen-specific Th2 cell activation, eosinophil and neutrophil accumulation, and serum IgE production in asthma; all of these features may play important roles in AR. To the best of our knowledge, only a few studies have assessed the feasibility of using IL-17 antagonists to treat AR. Thus, the principal objectives of the present study were, first, to determine the status of Th17 and Treg cells in the nasal mucosa of a mouse model of AR, and, second, to investigate the effects of IL-17 on such cells and the therapeutic efficacy of anti-IL-17 antibodies (Abs) in the context of AR. Anti-IL-17 Abs were given intranasally during the re-challenge of BALB/c mice with ovalbumin (OVA)-induced AR. We measured the numbers of nasal rubbing motions and sneezes, eosinophil and neutrophil levels, Th1, Th2, Th17, and Treg parameters in the nasal mucosa. Anti-IL-17 Abs markedly reduced the number of nasal rubbing motions and sneezes, decreased eosinophil and neutrophil infiltration, reduced Th2 and Th17 responses, and increased the Treg response. Anti-IL-17 Ab treatment protects against AR. These results will improve our understanding of AR pathogenesis and may lead to the development of novel therapeutic approaches for management of the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.